
Non-Sponsored Content
ASCO 2019 BREAST CANCER TRACK
SPOTLIGHT ON BREAST CANCER
By: Stijn van den Borne, MSc | Last updated: 3rd June 2019 | In: ASCO 2019 Annual Meeting, Breast Cancer, Chemotherapy, Conferences, Immunotherapy, Oncology, Targeted Therapies, Translational Research
Breast cancer has always been a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of therapeutic options to offer their patients – therapies that inherently have lower toxicity risks or the ability to reduce the duration of treatment as well as novel combinations with older therapeutics. The American Society of Clinical Oncology’s (ASCO) 2019 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.
ASCO 2019 Breast Cancer Keywords
#ASCO2019, abemaciclib, ado-trastuzumab emtansine, Afinitor, AI, AKT, AKT1, Aromasin, AstraZeneca, atezolizumab, AZ, AZD5363, Biocon, BRCA, capecitabine, capivasertib, carboplatin, CDK4/6, chemotherapy, cisplatin, CNS metastases, cobimetinib, Cotellic, cyclophosphamide, docetaxel, Eli Lilly, Ellence, endocrine therapy, epirubicin, ER-positive, eribulin mesylate, ESR1, everolimus, Exelixis, exemestane, Faslodex, Femara, fulvestrant, gemcitabine, Gemzar, Genentech, GnRH, goserilin, Halaven, HER2-negative, HER2-positive, Herceptin, hormonal therapy, HR-positive, Ibrance, Jiangsu HengRui Medicine, Kadcyla doxorubicin, Keytruda, Kisqali, LABC, lapatinib, letrozole, Lynparza, MacroGenics, margetuximab, MEK, Merck, MSD, mTor, Mylan, nab-paclitaxel pembrolizumab, neoadjuvant, neratinib, Nerlynx, Novartis, NSAI, OfS, Ogivri, olaparib, paclitaxel, palbociclib, PARP, PARPi, pCR, PD-L1, Perjeta, pertuzumab, Pfizer, Pharmorubicin, postmenopausal, PR-positive, premenopausal, Puma, pyrotinib, RAD001, RB1, ribociclib, Sanofi, T-DM1, TAC, taxane, Taxotere, Tecentriq, TNBC, trastuzumab, trastuzumab-dkst, triptorelin, Tykerb, Verzenio, vinolrebine, Xeloda, Zoladex
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2019 MediPaper Medical Communications Ltd. – ASCO 2019 Breast Cancer Track – #ASCO19 TNB MBC ABC – ASCO19 Breast Cancer
YOU MAY ALSO LIKE



































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients












































































































© Copyright 2019 MediPaper Medical Communications Ltd. – ASCO 2019 Breast Cancer Track – #ASCO19 TNB MBC ABC – ASCO19 Breast Cancer
Leave a Reply
Want to join the discussion?Feel free to contribute!